CORT
$13.59
Corcept Therapeutics
($.07)
(.51%)
CORT
Earnings Whisper ®
N/A
1st Quarter March 2020
Consensus:  $0.20
Revenue:  N/A
Thursday
May 21
4:05 PM ET
Score
Grade
Tweet Share Watch
Tweet Share Watch

What do you expect when CORT reports earnings?
Beat
Meet
Miss

Where is CORT's stock price going from here?
Up
Flat
Down
Stock chart of CORT
Analysts
Summary of analysts' recommendations for CORT
Score
Grade
Pivots
Resistance
$15.01
$14.69
$14.14

$13.82

Support
$13.27
$12.95
$12.40
Tweet
Growth
Description
Corcept Therapeutics Incorporated is a pharmaceutical company. It is engaged in the discovery, development and commercialization of drugs for the treatment of severe metabolic, psychiatric and oncologic disorders. The company focuses on disorders that are associated with a steroid hormone called cortisol. It is developing its lead product, CORLUX for the treatment of the psychotic features of psychotic major depression. Corcept Therapeutics Incorporated is headquartered in Menlo Park, California.
Peers
BioMarin PharmaceuticalRegeneron PharmaceuticalsVertex PharmaceuticalsInterCeptZoetisJohnson & JohnsonMylanUltragenyx PharmaceuticalBristol-Myers SquibbAlkermes